We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.45B
AUM Growth
-$251M
Cap. Flow
+$217M
Cap. Flow %
8.85%
Top 10 Hldgs %
50.47%
Holding
123
New
19
Increased
24
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.2M
2
GOSS icon
Gossamer Bio
GOSS
+$34.6M
3
XLRN
Acceleron Pharma
XLRN
+$26.3M
4
EPZM
Epizyme, Inc
EPZM
+$19.6M
5
BPMC
Blueprint Medicines
BPMC
+$18.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$10.4M
2
BLUE
bluebird bio
BLUE
+$10.2M
3
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10M
4
ANAB icon
AnaptysBio
ANAB
+$9.57M
5
ARGX icon
argenx
ARGX
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 65.35%
2 Consumer Discretionary 16.48%
3 Miscellaneous 14.54%
4 Technology 3.08%
5 Real Estate 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNAC icon
76
Cartesian Therapeutics
RNAC
$239M
$4.98M 0.2%
70,000
+50,000
+250% +$3.17M
IOVA icon
77
Iovance Biotherapeutics
IOVA
$4.17B
$4.75M 0.19%
500,000
– –
ALEC icon
78
Alector
ALEC
$230M
$4.68M 0.19%
+250,000
New +$4.73M
CRNX
79
DELISTED
Crinetics Pharmaceuticals
CRNX
$4.55M 0.19%
200,000
– –
MRUS
80
DELISTED
Merus
MRUS
$4.43M 0.18%
300,000
+93,875
+46% +$1.2M
MDGL icon
81
Madrigal Pharmaceuticals
MDGL
$11.9B
$4.38M 0.18%
35,000
-35,000
-50% -$4.35M
KDNY
82
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.98M 0.16%
200,000
– –
AKBA icon
83
Akebia Therapeutics
AKBA
$257M
$3.89M 0.16%
475,000
– –
SGMO
84
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.82M 0.16%
400,000
– –
RCUS icon
85
Arcus Biosciences
RCUS
$3.04B
$3.75M 0.15%
300,000
– –
TWST icon
86
Twist Bioscience
TWST
$9.02B
$3.48M 0.14%
150,000
– –
Z icon
87
Zillow
Z
$7.25B
$3.47M 0.14%
100,000
– –
NKTR icon
88
CALL
Nektar Therapeutics
NKTR
$2.27B
$3.36M 0.14%
6,667
-6,666
-50% -$3.95M
DNTH icon
89
Dianthus Therapeutics
DNTH
$5.87B
$3.29M 0.13%
12,500
– –
YI
90
111 Inc
YI
$29.3M
$2.92M 0.12%
45,000
– –
ACET icon
91
Adicet Bio
ACET
$76.1M
$2.73M 0.11%
3,571
– –
DTIL icon
92
Precision BioSciences
DTIL
$183M
$2.69M 0.11%
+5,000
New +$2.65M
GRTS
93
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.66M 0.11%
200,000
– –
TECX
94
Tectonic Therapeutic
TECX
$551M
$2.21M 0.09%
8,333
– –
CTMX icon
95
CytomX Therapeutics
CTMX
$621M
$2.15M 0.09%
200,000
+50,000
+33% +$739K
LRMR icon
96
Larimar Therapeutics
LRMR
$394M
$1.92M 0.08%
58,333
– –
ARAV
97
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.8M 0.07%
+256,269
New +$1.34M
WHWK
98
Whitehawk Therapeutics
WHWK
$231M
$1.4M 0.06%
103,893
– –
VRDN icon
99
Viridian Therapeutics
VRDN
$2.45B
$1.4M 0.06%
33,333
– –
TIGR
100
UP Fintech Holding
TIGR
$852M
$1.29M 0.05%
+100,000
New +$1.17M
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2019 Portfolio in Review

As of Q1 2019, Artal Group held 123 positions worth $2.45B, down 9.3% from $2.7B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $217M of net new capital in Q1 2019, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was NVIDIA: 16,800,000 shares worth $75.4M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 49% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.4M trimmed.

  • Artal Group's largest Q1 2019 buy was NVIDIA: 16,800,000 shares worth $75.4M.
  • Artal Group added most to Acceleron Pharma in Q1 2019, an estimated $26.3M increase.
  • Artal Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $10.4M.
  • Artal Group fully exited Clementia Pharmaceuticals Inc. in Q1 2019, selling an estimated $10M.
  • Artal Group's ten largest holdings make up 50% of its $2.45B portfolio in Q1 2019.
  • Artal Group opened 19 new positions and closed 19 in Q1 2019.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $2.45B.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.